Patents Assigned to Arch Development Corporation
  • Patent number: 8772261
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: July 8, 2014
    Assignee: Arch Development Corporation
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley
  • Patent number: 8318691
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: November 27, 2012
    Assignees: Arch Development Corporation, UAB Research Foundation
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley
  • Patent number: 7838512
    Abstract: Methods and compositions for enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit EGFR activity. The agents and inhibitors are administered in an amount effective to kill cancer cells, that is, the combined effect is sufficient so that cancer cell death is enhanced. If not administered at the same time, the DNA damaging agent(s) and tyrosine kinase inhibitors are administered close enough in time so they are still able to enhance cancer cell death. The methods and compositions are useful to treat neoplastic disease, e.g., pancreatic cancer.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: November 23, 2010
    Assignees: Arch Development Corporation, Dana-Farber Cancer Institute
    Inventors: Donald Kufe, Ralph R. Weichselbaum
  • Patent number: 7799535
    Abstract: The present invention provides a yeast cell based system for determining factors that control the folding of amyloid proteins of diverse origins. Further the present invention provides methods of using such a system to screen for reagents that affect amyloid formation, a process that is integral to several devastating human disease including Creutzfeld-Jacob disease (CJD), fatal familial insomnia (FFI), Gertsmann-Straussler-Scheinker (GSS) syndrome, and kuru. The system of the present invention provides a rapid screening system to quickly and cheaply identify reagents that affect the folding and aggregation properties of the target protein.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: September 21, 2010
    Assignee: ARCH Development Corporation
    Inventor: Susan Lindquist
  • Patent number: 7235366
    Abstract: The invention relates generally to compositions of and methods for obtaining opioid receptor polypeptides. The invention relates as well to polynucleotides encoding opioid receptor polypeptides, the recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant opioid receptor polypeptides. By way of example, the invention discloses the cloning and functional expression of at least three different opioid receptor polypeptides. The invention includes as well, methods for using the isolated, recombinant receptor polypeptides in assays designed to select and improve substances capable of interacting with opioid receptor polypeptides for use in diagnostic, drug design and therapeutic applications.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 26, 2007
    Assignee: ARCH Development Corporation
    Inventors: Graeme I. Bell, Terry Reisine, Kazuki Yasuda
  • Patent number: 7227177
    Abstract: A particle, includes a semiconductor nanocrystal. The nanocrystal is doped.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: June 5, 2007
    Assignee: Arch Development Corporation
    Inventors: Philippe Guyot-Sionnest, Moonsub Shim, Conjun Wang
  • Patent number: 7192711
    Abstract: Disclosed are novel nucleic acid and peptide compositions comprising methylthioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and identification of tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: March 20, 2007
    Assignee: Arch Development Corporation
    Inventor: Olufunmilayo I. Olopade
  • Patent number: 7184582
    Abstract: A method, system and computer readable medium for an intelligent search display into which an automated computerized image analysis has been incorporated. Upon viewing an unknown mammographic case, the display shows both the computer classification output as well as images of lesions with known diagnoses (e.g., malignant vs. benign) and similar computer-extracted features. The similarity index used in the search can be chosen by the radiologist to be based on a single feature, multiple features, or on the computer estimate of the likelihood of malignancy. Specifically the system includes the calculation of features of images in a known database, calculation of features of an unknown case, calculation of a similarity index, display of the known cases along the probability distribution curves at which the unknown case exists.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: February 27, 2007
    Assignee: Arch Development Corporation
    Inventors: Maryellen L. Giger, Carl J. Vyborny, Zhimin Huo, Li Lan
  • Patent number: 7169764
    Abstract: Disclosed is a smooth muscle cell specific promoter, the SM22? gene promoter as well as the murine cDNA and genomic SM22? nucleic acid sequences. Also disclosed are methods of preventing restenosis following balloon angioplasty and methods of treating asthma based on inhibition of smooth muscle cell proliferation by expressing cell cycle control genes, or contraction inhibiting peptides in smooth muscle cells, under the control of the SM22? promoter.
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: January 30, 2007
    Assignee: Arch Development Corporation
    Inventors: Michael S. Parmacek, Julian Solway
  • Publication number: 20060251626
    Abstract: This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.
    Type: Application
    Filed: June 9, 2006
    Publication date: November 9, 2006
    Applicant: Arch Development Corporation
    Inventors: Jeffrey Leiden, Eric Svensson
  • Patent number: 7133203
    Abstract: A method and apparatus for control of optical trap arrays and formation of particle arrays. The method and apparatus provides a laser and a time variable diffractive optical element to allow dynamic control of optical trap arrays and consequent control of particle arrays and also the ability to manipulate singular objects using a plurality of optical traps.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: November 7, 2006
    Assignee: Arch Development Corporation
    Inventors: David G. Grier, Eric R. Dufresne
  • Patent number: 7078396
    Abstract: A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: July 18, 2006
    Assignee: ARCH Development Corporation
    Inventors: Ching Song, Shutsung Liao
  • Patent number: 7070968
    Abstract: The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: July 4, 2006
    Assignees: ARCH Development Corporation, Dana Farber Cancer Institute
    Inventors: Donald Kufe, Ralph R. Weichselbaum
  • Patent number: 7043066
    Abstract: A method, system and computer readable medium for computerized processing of chest images including obtaining a digital first image of a chest (S100); producing a second image which is a mirror image (S300) of the first image; performing image warping on one of the first and second images to produce a warped image (S400) which is registered to the other of the first and second images; and subtracting the warped image from the other image to generate a subtraction image (S600).
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: May 9, 2006
    Assignee: Arch Development Corporation
    Inventors: Kunio Doi, Qiang Li, Shigehiko Katsuragawa, Takayuki Ishida
  • Patent number: 7012069
    Abstract: A compound of formula (I): Each of R1, R2, R3, R4, R4?, R5, R6, R7, R11, R12, R15, R16, and R17, independently, is hydrogen, halo, alkyl, haloalkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or alkyl that is optionally inserted with —NH—, —N(alkyl)—, —O—, —S—, —SO—, —SO2—, —O—SO2—, —SO2—O—, —SO3—O—, —CO—, —CO—O—, —O—CO—, —CO—NR?—, or —NR?—CO—; or R3 and R4 together, R4 and R5 together, R5 and R6 together, or R6 and R7 together are eliminated so that a C?C bond is formed between the carbons to which they are attached; each of R8, R9, R10, R13, and R14, independently, is hydrogen, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; n is 0, 1, or 2; A is alkylene, alkenylene, or alkynylene; and each of X, Y, and Z, independently, is alkyl, haloalkyl, —OR?, —SR?, —NR?R?, —N(OR?)R?, or —N(SR?)R?; or X and Y together are ?O, ?S, or ?NR?; wherein each of R? and R?, independently, is hydrogen, alkyl, or haloalkyl.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: March 14, 2006
    Assignee: ARCH Development Corporation
    Inventors: Ching Song, Shutsung Liao
  • Patent number: 6999899
    Abstract: A method and system for monitoring at least one of a system, a process and a data source. A method and system have been developed for carrying out surveillance, testing and modification of an ongoing process or other source of data, such as a spectroscopic examination. A signal from the system under surveillance is collected and compared with a reference signal, a frequency domain transformation carried out for the system signal and reference signal, a frequency domain difference function established. The process is then repeated until a full range of data is accumulated over the time domain and a Sequential Probability Ratio Test (“SPRT”) methodology applied to determine a three-dimensional surface plot characteristic of the operating state of the system under surveillance.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: February 14, 2006
    Assignee: ARCH Development Corporation
    Inventors: Kenneth C. Gross, Stephan W. Wegerich, Cynthia Criss-Puszkiewicz, Alan D. Wilks
  • Patent number: 6984619
    Abstract: Methods and pharmaceuticals for inhibiting or preventing metastasis formation in animals, including humans, having primary tumors, through the administration of phosphorothioates including their thiol and disulfide metabolites are disclosed. These compounds stimulate angiostatin levels, inhibit matrix metalloproteinases (MMPs), and stimulate manganese superoxidase dismutase (MnSOD). Phosphorothioates, of which amifostine is an example, can be administered as a combination therapy with traditional cancer therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormone therapy and gene-therapy. Inhibition or prevention of metastasis by phosphorothioates is independent of tumor type, including adenocarcinomas and sarcomas.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: January 10, 2006
    Assignees: Arch Development Corporation, Board of Regents, The University of Texas System
    Inventors: David J. Grdina, Luka Milas
  • Patent number: 6972196
    Abstract: Alkanethiols of formula (1) and the enantiomers of the alkanethiol of formula (1): HS-L-Q-T??(1), and disulfides of formula (3) and the enantiomers of the disulfide of formula (3): T-Q-L S-S-J??(3), where -T is a moiety of formula (2) R1 and R2 are each individually selected from the group consisting of H and OH; a is 0 to 3; b is 0 to 3; and indicates that the chirality of the carbon atom to which it is attached is either R or S; may form inert surfaces that prevent the unwanted adsorption of proteins and cells.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: December 6, 2005
    Assignee: Arch Development Corporation
    Inventors: Milan Mrksich, Yan-Yeung Luk
  • Patent number: 6939604
    Abstract: A particle, includes a semiconductor nanocrystal. The nanocrystal is doped.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: September 6, 2005
    Assignee: Arch Development Corporation
    Inventors: Philippe Guyot-Sionnest, Moonsub Shim, Conjun Wang
  • Patent number: 6916610
    Abstract: Generation of longer cDNA fragments from SAGE tags for gene identification (GLGI) is disclosed. This method converts SAGE tags, which are about 10 base pairs in length, into their corresponding 3? cDNA fragments covering hundred bases. This added information provides for more accurate genome-wide analysis and overcomes the inherent deficiencies of SAGE. The generation of longer cDNA fragments from isolated and purified protein fragments for gene identification is also disclosed. This method converts a short amino acid sequence into extended versions of the DNA sequences encoding the protein/protein fragment and additional 3? end sequences of the gene encoding the protein. This additional sequence information allows gene identification from purified protein sequences. The invention also provides a high-throughput GLGI procedure for identifying genes corresponding to a set of unidentified SAGE tags.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: July 12, 2005
    Assignee: Arch Development Corporation
    Inventors: San Ming Wang, Jian-jun Chen, Janet D. Rowley